Pharmaceutical Stocks

Pharmaceutical stocks have grown tremendously as medicine advances. With diseases like Covid-19, diabetes, liver disease and other illnesses affecting more and more of the population, pharmaceutical companies are racing to find cures – further advancing medicine and driving pharma stock prices higher.

Big Pharma corporations like AstraZeneca, Merck & Co., Pfizer, and Johnson & Johnson are leading the charge against the novel coronavirus, competing with smaller biotech names — such as Moderna and Novavax. The race to find a Covid-19 vaccine has sent both pharma and biotech stocks to the moon.

Wait on Arena’s Weight-Loss Drug

By James Brumley, InvestorPlace Feature Writer
The FDA is all set to rule on Arena Pharmaceuticals' weight loss drug lorcaserin, and things look good, but its approval might already be priced in.

The Obamacare Ruling: 5 Investing Scenarios

By Susan J. Aluise, Aviation, Auto & Transportation Writer
The Supreme Court's looming decision will surely create winners and losers among health care stocks. Here's an investor's guide to the possible outcomes.

Don’t Buy Pharma Stocks — Buy THESE Pharma Stocks

By James Brumley, InvestorPlace Feature Writer
If your sliver of the pharma pie is too small, it's easy to fall into the "any old pharma stock will do" trap. Keep your eye on the prize with these must-own names.

Pfizer to Spin Off Its Animal Health Biz

By Angela Nazworth, InvestorPlace Writer
Pfizer announced Thursday its plan to spin off its animal health business into a stand-alone company named Zoetis.

4 Stocks Buffett May Be Buying in Europe

By Bryan Perry
A look at the Oracle's buying behavior in the past clues you in to where his cash is likely being funneled now.

Gilead Sciences’ HIV Drugs Clear a Hurdle

By Susan J. Aluise, Aviation, Auto & Transportation Writer
Full FDA approval should come next -- but if not, watch out, because Gilead is very heavily dependent on its HIV drug lineup, and patents will be expiring.

Obesity: The Next Investment Driver

By James Brumley, InvestorPlace Feature Writer
The global market for weight-control products of all types is forecast to hit $53 billion in just five years, and several companies are primed to profit.

Pfizer is Still a Pharmaceutical-Giant Buy

By Louis Navellier, Editor, Growth Investor
Despite a slowdown in sales as Lipitor becomes a generic drug, pharma giant Pfizer is still a very good buy, and a great play for your portfolio.

Pfizer: Profits Drop, Beat Forecasts

By Christopher Freeburn, InvestorPlace Writer
Pfizer's first-quarter earnings and revenue declined, led by dropping sales for Lipitor, but beat analysts’ forecasts, even as it lowered its outlook.

Watson Pharmaceuticals Is No Ordinary Generic

By Louis Navellier, Editor, Growth Investor
Watson Pharmaceuticals is an outstanding company that grows earnings and revenues every year in the tough generic pharma space. Consider this a top buy.

AstraZeneca CEO Resigns, Shares Drop

By Christopher Freeburn, InvestorPlace Writer
CEO David Brennan departs after the company reported lower earnings and sales for the last quarter and a diminished outlook for the year.

Invest Smarter in the New Biotech Landscape

By Traders Reserve
Big phara and biotech companies are slowly becoming one and the same. Investors can profit from the merge with solid research and timing.

Will JNJ Rise From the Ashes?

By James Brumley, InvestorPlace Feature Writer
No need to mince words -- Johnson & Johnson is in a pretty good mess right now. But new CEO Alex Gorsky might have the tools to turn things around.

Abbott Laboratories Is Cheaper Than You Think

By Dividend Growth Investor
Abbott Labs financial statements provide information on earnings per share that suggest the stock is undervalued, with a possible P/E ratio better than market

Stock Pick of The Day: Dyax

By Louis Navellier, Editor, Growth Investor
Dyax is a maker of anti-inflammation drugs, an area with a growing base of patients. While in the early stages of growth, the company shows great promise.

5 Global Stock Buys and 2 Sells

By Louis Navellier, Editor, Growth Investor
There a number of outstanding opportunities in European stocks, as long as you can do the work to find them. Here are 5 top performers to start with now.

Here Comes a Bidding War for Amylin

By Gene Marcial, InvestorPlace Contributor
Approval of its diabetes drug has Big Pharma banging on its door, with Bristol-Myers Squibb already said to have offered $3.5 billion, or $22 per share.

4 Biotech ETFs for a Healthy Portfolio

By Susan J. Aluise, Aviation, Auto & Transportation Writer
The sector is coming back strong, and a diversified ETF is the best way to play it.

Generic Versions of Boniva Approved By the FDA

By InvestorPlace Staff
The FDA approved the first generic versions of osteoporosis drug Boniva, allowing manufacturers like Apotex, Orchid Healthcare and Mylan to make the drug.
Load More